USC PE-GCS: Optimizing Engagement of Hispanic Colorectal Cancer Patients in Cancer Genomic Characterization Studies

USC PE-GCS：优化西班牙裔结直肠癌患者参与癌症基因组特征研究

基本信息

批准号：
10696237
负责人：
JOHN D. CARPTEN
金额：
$ 138.61万
依托单位：
UNIVERSITY OF SOUTHERN CALIFORNIA
依托单位国家：
美国
项目类别：
财政年份：
2021
资助国家：
美国
起止时间：
2021-09-22 至 2027-08-31
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10696237
关键词：
Address Advocate African American population Age Age Years Area Behavioral Behavioral Sciences Biology Biomedical Research California Cancer Etiology Cause of Death Cessation of life Characteristics Clinic Clinical Clinical Data Collaborations Colorectal Cancer Communication Communities Community Healthcare Community Outreach Consent Data Analyses Diagnosis Disease Ethnic Population Etiology Fasting Fostering Genome Genomics Goals Health Services Accessibility High Prevalence Hispanic Hispanic Populations Incidence Knowledge Laboratories Latino Latino Population Malignant Neoplasms Medical Mexican Molecular Not Hispanic or Latino Outcome Patient Preferences Patient-Focused Outcomes Patients Positioning Attribute Process Rectal Cancer Reporting Research Risk Scientist Subgroup Taxonomy Techniques Technology Testing The Cancer Genome Atlas Time Treatment Factor Underrepresented Minority Underserved Population cancer care cancer genome cancer genomics caucasian American clinical translation colon cancer patients community engagement demographics design early onset colorectal cancer genome sequencing genomic data health care settings improved member minority patient novel novel strategies participant enrollment patient engagement patient population research study socioeconomics translational cancer research translational genomics

项目摘要

ABSTRACT Colorectal Cancer (CRC) is the second leading cause of cancer death in the US. Hispanic/Latinos are the largest and fasting growing ethnic group in the US, and cancer is the leading cause of death among H/L in the US. Therefore, we need to fully understand the full complexity of the molecular etiology of cancer in this ethnic group. For instance, although incidence rates of CRC are lower among Latinos as compared to Whites or African Americans, Hispanics with metastatic disease have shorter overall survival when adjusted for health care setting, demographics, disease characteristics and treatment factors. H/L also tend to be diagnosed at a younger age and with higher stage, and we have previously reported that Mexican H/L in California have the greatest proportion of young (<50 years of age) diagnoses compared to other H/L subgroups. Moreover, Mexican H/L showed higher prevalence of rectal cancer cases compared to other H/L and NHW. Although socio-economics and access to care might influence these differences, we need to take a complete look at the biology of disease in this ethnic group to determine once and for all if these clinical differences are related to differences in molecular etiology. The Cancer Genome Atlas has provided a deep overview of the molecular taxonomy of CRC in 594 cases, however, less than 1% of the cases (n=5) were H/L. Therefore, it is imperative for us to take more detailed assessment of the molecular genomic landscape of CRC in H/L. One of the major issues likely limiting our ability to perform these large genomic initiatives in minority patients is that Patient or Participant Engagement practices may not been investigated to identify best practices for accruing and consenting patients into clinical translational biomedical research studies. This concept of Participant Engagement is critically important for both the patients and the translational cancer research community. Optimizing and improving our approaches for directly engaging patients at initial contact, throughout the course of a translational genomic study, and during the time of return of results is likely to lead to stronger relationships between the medical community and patients, but could also lead to significant improvement in outcomes for patients and for the cancer care community as a whole. As such, we propose the creation of the USC Center for Optimization of Participant Engagement in Cancer Characterization (COPECC) with a focus on optimizing the engagement of Latinos in CRC Genomic Characterization research studies. USC COPECC would serve as a member of the NCI U2C Participant Engagement and Cancer Genome Sequencing (PE-CGS) Network. Our investigative team includes experts in all relevant areas of research for genomic characterization, participant engagement, and engagement optimization. We have an established platform for consenting patients into cancer genomics studies that will serve as a standard process. The overall goal of USC COPECC is to generate results on participant engagement optimization and CRC genomic research that will be shared with the broader community to distribute best practices for engaging Latinos in hopes of improving overall outcomes for CRC in this underserved population.

抽象的结直肠癌 (CRC) 是美国癌症死亡的第二大原因。西班牙裔/拉丁裔人数最多在美国，癌症是 H/L 族裔的首要死因。因此，我们需要充分了解该族群癌症分子病因学的全部复杂性。例如，尽管与白人或非洲人相比，拉丁裔的结直肠癌发病率较低根据医疗保健环境进行调整后，患有转移性疾病的美国人、西班牙裔人的总体生存期较短，人口统计、疾病特征和治疗因素。 H/L 也往往在较年轻的时候被诊断出来并且阶段更高，我们之前报道过加利福尼亚州的墨西哥 H/L 拥有最大的与其他 H/L 亚组相比，年轻（<50 岁）诊断的比例。此外，墨西哥 H/L 与其他 H/L 和 NHW 相比，直肠癌病例的患病率更高。尽管社会经济获得护理的机会可能会影响这些差异，我们需要全面了解疾病的生物学在这个种族群体中一劳永逸地确定这些临床差异是否与分子差异有关病因学。癌症基因组图谱深入概述了 CRC 的分子分类学 594 然而，只有不到 1% 的病例 (n=5) 为 H/L。因此，我们有必要采取更详细的措施 H/L 中 CRC 的分子基因组景观评估。可能限制我们能力的主要问题之一在少数族裔患者中执行这些大型基因组计划的关键是患者或参与者参与实践可能没有进行调查以确定吸引和同意患者进入临床转化的最佳实践生物医学研究。参与者参与的概念对于患者和患者都至关重要以及转化癌症研究界。优化和改进我们的直接方法在初次接触时、整个转化基因组研究过程中以及在此期间让患者参与进来结果返回的结果可能会导致医学界和患者之间的关系更加牢固，但是还可以显着改善患者和癌症护理界的治疗结果所有的。因此，我们建议创建南加州大学参与者参与优化中心癌症表征 (COPECC)，重点是优化拉丁美洲人在 CRC 基因组中的参与表征研究。 USC COPECC 将成为 NCI U2C 参与者的成员参与和癌症基因组测序 (PE-CGS) 网络。我们的调查团队包括以下领域的专家基因组表征、参与者参与和参与的所有相关研究领域优化。我们拥有一个已建立的平台，用于同意患者参与癌症基因组学研究，这将作为标准流程。 USC COPECC 的总体目标是在参与者参与方面取得成果优化和 CRC 基因组研究将与更广泛的社区共享，以实现最佳分发吸引拉丁美洲人参与的做法，希望改善这一服务不足的人群中结直肠癌的总体结果。